Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Pharmaceutical Industry’s Profit Rises 40 Percent In First Five Months Of 2008

This article was originally published in PharmAsia News

Executive Summary

National Development and Reform Commission figures show that for the first five months of 2008, the pharmaceutical industry recorded a gross industrial output value of 311.6 billion yuan ($45.6 billion) and a profit of 27.8 billion yuan ($4.07 billion), up 29 percent and 43.6 percent respectively from the same period last year. The profit represents 22.7 percentage points higher than the national industry average, placing the sector third in the country's 12 major industries. Pharmaceutical raw materials overtook Chinese patent medicine as the second largest profit source for the sector. NDRC sees continuous rapid growth with investment returns improving. However, the industry faces major challenges such as soaring raw material prices for energy, blood product shortages and need for standardized distribution control, as well as slowdown in investment. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC069055

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel